Literature DB >> 34593682

Indwelling Central Venous Catheters Drive Bloodstream Infection During Veno-venous Extracorporeal Membrane Oxygenation Support.

Adwaiy Manerikar1, Satoshi Watanabe2, Viswajit Kandula1, Azad Karim1, Sanket Thakkar1, Mark Saine1, Samuel S Kim1, Rafael Garza-Castillon1, David D Odell1, Ankit Bharat1,2, Chitaru Kurihara1.   

Abstract

Blood stream infection (BSI) is a potentially lethal complication in patients receiving extracorporeal membrane oxygenation (ECMO). It may be particularly common in patients with veno-venous ECMO due to their long hospitalization in the intensive care unit. Given that these patients have concurrent indwelling central venous catheters (CVC), it is unclear whether the ECMO circuit, CVC, or both, contribute to BSI. This study evaluated the risk factors associated with BSI in patients receiving veno-venous ECMO in a single institution study of 61 patients from 2016 through 2019. All ECMO catheters and the circuit oxygenator fluid were aseptically collected and analyzed for microorganisms at the time of decannulation. New BSI was diagnosed in 15 (24.6%) patients and increased mortality by threefold. None of the ECMO catheters or oxygenator fluid were culture positive. BSI increased with CVC use of over 8 days and was significantly lowered when CVC were exchanged by day 8 compared with patients with exchanges at later points (15.0% vs. 42.8%, p = 0.02). Median length of CVC use in the BSI-negative and BSI-positive group were 6.3 ± 5.0 and 9.4 ± 5.1, respectively (p = 0.04). In summary, BSI is a potentially lethal complication in patients receiving ECMO. Indwelling CVC, not the ECMO circuitry, is the likely contributor for BSI, and exchanging CVC by day 8 can reduce the incidence of BSI.
Copyright © ASAIO 2021.

Entities:  

Mesh:

Year:  2022        PMID: 34593682      PMCID: PMC8958168          DOI: 10.1097/MAT.0000000000001575

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   3.826


  28 in total

1.  Therapeutic anticoagulation-free extracorporeal membrane oxygenation as a bridge to lung transplantation.

Authors:  Jonathan Tomasko; Sunil M Prasad; David O Dell; Malcolm M DeCamp; Ankit Bharat
Journal:  J Heart Lung Transplant       Date:  2016-05-06       Impact factor: 10.247

2.  Nosocomial infections in adult cardiogenic shock patients supported by venoarterial extracorporeal membrane oxygenation.

Authors:  Matthieu Schmidt; Nicolas Bréchot; Sarah Hariri; Marguerite Guiguet; Charles Edouard Luyt; Ralouka Makri; Pascal Leprince; Jean-Louis Trouillet; Alain Pavie; Jean Chastre; Alain Combes
Journal:  Clin Infect Dis       Date:  2012-09-18       Impact factor: 9.079

3.  Central venous catheterization: a prospective, randomized, double-blind study.

Authors:  Mervyn Mer; Adriano Gianmaria Duse; Jacqueline Suzanne Galpin; Guy Antony Richards
Journal:  Clin Appl Thromb Hemost       Date:  2008-07-01       Impact factor: 2.389

Review 4.  Venovenous extracorporeal membrane oxygenation for acute respiratory failure : A clinical review from an international group of experts.

Authors:  Eddy Fan; Luciano Gattinoni; Alain Combes; Matthieu Schmidt; Giles Peek; Dan Brodie; Thomas Muller; Andrea Morelli; V Marco Ranieri; Antonio Pesenti; Laurent Brochard; Carol Hodgson; Cecile Van Kiersbilck; Antoine Roch; Michael Quintel; Laurent Papazian
Journal:  Intensive Care Med       Date:  2016-03-23       Impact factor: 17.440

5.  Feasibility of Venovenous Extracorporeal Membrane Oxygenation Without Systemic Anticoagulation.

Authors:  Chitaru Kurihara; James M Walter; Azad Karim; Sanket Thakkar; Mark Saine; David D Odell; Samuel Kim; Rade Tomic; Richard G Wunderink; G R Scott Budinger; Ankit Bharat
Journal:  Ann Thorac Surg       Date:  2020-03-12       Impact factor: 4.330

Review 6.  Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.

Authors:  Rinaldo Bellomo; Claudio Ronco; John A Kellum; Ravindra L Mehta; Paul Palevsky
Journal:  Crit Care       Date:  2004-05-24       Impact factor: 9.097

7.  Factors associated with outcomes of patients on extracorporeal membrane oxygenation support: a 5-year cohort study.

Authors:  Cecile Aubron; Allen C Cheng; David Pilcher; Tim Leong; Geoff Magrin; D Jamie Cooper; Carlos Scheinkestel; Vince Pellegrino
Journal:  Crit Care       Date:  2013-04-18       Impact factor: 9.097

8.  Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China.

Authors:  Xin Li; Zhen Guo; Bailing Li; Xiaolin Zhang; Rui Tian; Wei Wu; Zhongwei Zhang; Yunfei Lu; Nan Chen; Sean P Clifford; Jiapeng Huang
Journal:  ASAIO J       Date:  2020-05       Impact factor: 2.872

Review 9.  Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases.

Authors:  Kollengode Ramanathan; David Antognini; Alain Combes; Matthew Paden; Bishoy Zakhary; Mark Ogino; Graeme MacLaren; Daniel Brodie; Kiran Shekar
Journal:  Lancet Respir Med       Date:  2020-03-20       Impact factor: 30.700

10.  Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry.

Authors:  Ryan P Barbaro; Graeme MacLaren; Philip S Boonstra; Theodore J Iwashyna; Arthur S Slutsky; Eddy Fan; Robert H Bartlett; Joseph E Tonna; Robert Hyslop; Jeffrey J Fanning; Peter T Rycus; Steve J Hyer; Marc M Anders; Cara L Agerstrand; Katarzyna Hryniewicz; Rodrigo Diaz; Roberto Lorusso; Alain Combes; Daniel Brodie
Journal:  Lancet       Date:  2020-09-25       Impact factor: 79.321

View more
  1 in total

1.  Risk factors for bloodstream infection (BSI) in patients with severe acute respiratory distress syndrome (ARDS) supported by veno-venous extracorporeal membrane oxygenation (VV-ECMO).

Authors:  Liuting Yang; Min Li; Sichao Gu; Yingying Feng; Xu Huang; Yi Zhang; Ye Tian; Xiaojing Wu; Qingyuan Zhan; Linna Huang
Journal:  BMC Pulm Med       Date:  2022-09-28       Impact factor: 3.320

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.